News Sentiment

IMCR sentiment intelligence

Immunocore Holdings Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 31.95 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-1.7% over one week, +10.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction -1.7% Price digesting
Trend fit Trend inactive 10.3% over four weeks
Fair value -21.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 36
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
TradingView 8
simplywall.st 6
Stock Titan 6
TradingKey 5
Stock Traders Daily 4
Moomoo 2
Investing.com Nigeria 1

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 19
Analyst action 7
Balance sheet 3
Guidance 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-54 of 54
Moomoo Direct company coverage

Immunocore Reports 14.3-Month Survival in Phase 1/2 Trial of Advanced Melanoma Drug Candidate

Immunocore Holdings, a late-stage biotechnology company, announced updated data from its Phase 1/2 clinical trial of IMC-F106C (brentuximab vedotin) as a treatment for advanced cutaneous melanoma. The data indicated a median overall survival of 14.3 months, with a 6-month overall

Tone
Positive 74/100
Event
Market update
Published
02 Jun 2026 09:09
Source
Moomoo
Intellectia AI Direct company coverage

IMCR Financials: Revenue Breakdown, Margins & Competitor Comparison

This article provides an in-depth financial analysis of Immunocore Holdings PLC (IMCR), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's primary revenue driver is product sales, accounting for 96.6% of total sales, alongside

Tone
Positive 64/100
Event
Earnings
Published
02 Jun 2026 04:09
Source
Intellectia AI
Stock Titan Direct company coverage

Immunocore trial: brenetafusp 14.3-month survival in melanoma

Immunocore announced updated Phase 1/2 data for brenetafusp in heavily pretreated, HLA-A*02:01-positive advanced melanoma patients, showing a median overall survival of 14.3 months and a 6-month survival rate of 87%. The data, presented at ASCO 2026, also indicated a 52% disease

Tone
Positive 75/100
Event
Market update
Published
01 Jun 2026 00:40
Source
Stock Titan
Investing News Network Direct company coverage

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore Holdings plc announced updated Phase 1/2 clinical trial data for brenetafusp in patients with advanced melanoma. The monotherapy showed an 87% 6-month overall survival rate and a 52% disease control rate in heavily pretreated patients, supporting the 160 mcg dose for t

Tone
Positive 71/100
Event
Market update
Published
31 May 2026 14:10
Source
Investing News Network
Stock Titan Direct company coverage

Immunocore (IMCR) director awarded 27,492 share options

Immunocore Holdings plc director Roy Steven Herbst was granted 27,492 share options with an exercise price of $28.52 per share, set to expire on May 26, 2036. These options will vest by May 27, 2027, or the day before the company's next annual general meeting, contingent on his c

Tone
Neutral 50/100
Event
Market update
Published
31 May 2026 03:09
Source
Stock Titan